Sensei Biotherapeutics Reports Full Year 2025 Results, Announces Strategic Faeth Acquisition and \$200 Million Financing

Key Highlights for Investors

• Major Acquisition: Sensei Biotherapeutics (Nasdaq: SNSE) completed the acquisition of Faeth Therapeutics, bringing PIKTOR, a promising multi-node PI3K/AKT/mTOR pathway inhibitor, into its pipeline and making it the lead program.
• Significant Capital Raise: Sensei secured a \$200 million private placement, substantially strengthening its cash position and financial flexibility to advance key clinical milestones.
• Clinical Milestones Ahead: The capital infusion is expected to fund topline data readouts from the ongoing Phase 2 trial of PIKTOR in advanced endometrial cancer and the planned Phase 1b trial in HR+/HER2- advanced breast cancer, both targeted for year-end 2026.
• Improved Financial Position: Despite a decrease in cash and lower operating expenses, the company reduced its net loss year-over-year and expects the recent financing to support its clinical programs through critical inflection points.
• Pipeline Expansion and Potential: PIKTOR’s mechanism may provide more comprehensive pathway suppression than single-agent approaches, with an emerging tolerability profile that compares favorably to existing therapies.

Detailed Report

BOSTON, Mass., March 30, 2026 — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) has released its financial results for the full year ended December 31, 2025, alongside a significant corporate update that may have far-reaching implications for the company’s future and its shareholders.

The highlight of the year was the strategic acquisition of Faeth Therapeutics, which brings PIKTOR — an all-oral, proprietary combination of serabelisib and sapanisertib — into Sensei’s pipeline as its new lead program. PIKTOR is designed to target multiple nodes of the PI3K/AKT/mTOR pathway, a critical oncogenic pathway implicated in various solid tumors, including endometrial and breast cancers.

PIKTOR Clinical Development and 2026 Milestones

The company is advancing two pivotal clinical trials for PIKTOR:

• The ongoing Phase 2 trial in advanced endometrial cancer (Study FTH-PIK-201).
• The planned Phase 1b trial in HR+/HER2- advanced breast cancer (Study FTH-PIK-101).

Data readouts and initiation of these studies are expected by the end of 2026, positioning Sensei for potential value inflection points in the coming year. Additionally, the company is exploring further development opportunities for PIKTOR in ovarian and lung cancers.

Financial Performance for 2025

• Cash Position: As of December 31, 2025, Sensei held \$21.2 million in cash, cash equivalents, and marketable securities, compared with \$41.3 million at the end of 2024. This figure does not include the proceeds from the recently announced \$200 million private placement, which will significantly strengthen the balance sheet and extend the cash runway.
• R&D Expenses: Research and development expenses dropped to \$11.0 million (from \$18.6 million in 2024), reflecting cost reductions across personnel, facilities, and clinical expenses.
• G&A Expenses: General and administrative expenses were \$11.3 million, down from \$13.0 million, as lower personnel costs offset higher restructuring and consulting costs associated with the business realignment and acquisition.
• Net Loss: Net loss narrowed to \$21.1 million (or \$16.72 per share) from \$30.2 million (\$24.01 per share) in the prior year, reflecting the company’s focus on cost discipline.
• Balance Sheet: As of year-end 2025, total assets were \$22.9 million, total liabilities \$4.3 million, and total stockholders’ equity \$18.6 million.

Strategic and Shareholder Considerations

Shareholder Impact: The acquisition of Faeth Therapeutics and the \$200 million capital raise are highly material events that may significantly affect Sensei’s valuation and investor sentiment. The company now has the resources to progress PIKTOR through key clinical milestones that, if successful, could unlock substantial value. Furthermore, management highlighted the potential for PIKTOR to offer more comprehensive pathway suppression and a favorable tolerability profile versus current therapies – a key differentiator in a competitive oncology landscape.

Guidance and Risks: Management expects topline Phase 2 endometrial cancer data and the initiation of the Phase 1b breast cancer trial by the end of 2026. However, the company cautions that these forward-looking statements are subject to numerous risks and uncertainties, including clinical development outcomes, regulatory hurdles, and integration of the Faeth acquisition.

Other Pipeline News: Sensei is also completing a Phase 1/2 trial of solnerstotug, its VISTA inhibitor, in advanced solid tumors, broadening its pipeline and adding further optionality for investors.

Contact Information

Investor Contact: Stephanie Ascher, Precision AQ ([email protected])
Media Contact: Patrick Schmidt, Consort Partners ([email protected])

Disclaimer

This article is for informational purposes only. It is not investment advice. Forward-looking statements discussed are subject to risks and uncertainties that may cause actual results to differ materially. Investors should review official filings and risk disclosures before making investment decisions. The company does not undertake any obligation to update forward-looking statements.

View Sensei Biotherapeutics, Inc. Historical chart here